Factors predicting Medicare national coverage: an empirical analysis
- PMID: 22193418
- DOI: 10.1097/MLR.0b013e318241eb40
Factors predicting Medicare national coverage: an empirical analysis
Abstract
Background: Interventions considered to be particularly controversial or expected to significantly impact the Medicare program in the United States are considered in National Coverage Determinations. Medicare coverage for such interventions is limited to those deemed "reasonable and necessary" for the diagnosis or treatment of an illness or injury. What constitutes reasonable and necessary has not, however, been clearly defined.
Objective: To determine factors associated with positive National Coverage Determinations.
Research design: A dataset of coverage decisions from 1999 to 2007 (n=195) was created with the following variables: direction of coverage decision; quality of supporting evidence; availability of alternative interventions; cost-effectiveness of intervention; type of intervention; coverage requestor; and year of decision. Univariate and multivariate logistic regression analysis was used to determine factors associated with positive coverage.
Results: The following variables were independently associated with positive Medicare coverage: good or fair quality supporting evidence (adjusted odds ratio, OR=6.04, P<0.01); presence of an alternative intervention (OR=0.130, P<0.01); no associated estimate of cost-effectiveness (OR=0.190, P<0.05). In addition, in comparison with coverage decisions made in the years 1999 to 2001, those made in the years 2002 to 2003, 2004 to 2005, and 2006 to 2007, were associated with positive coverage [ORs of 0.311 (P<0.05), 0.310 (P<0.1), and 0.109 (P<0.01), respectively].
Conclusions: Findings suggest that good or fair quality supporting evidence is a strong predictor of positive coverage. Availability of alternative interventions, more recent decisions, and lack of an associated estimate of cost-effectiveness are associated with a decreased likelihood of positive coverage. The findings highlight Medicare's move to evidence-based coverage decisions, and suggest that coverage decisions are influenced by the availability of cost-effectiveness evidence.
Similar articles
-
Does Medicare have an implicit cost-effectiveness threshold?Med Decis Making. 2010 Jul-Aug;30(4):E14-27. doi: 10.1177/0272989X10371134. Epub 2010 Jun 15. Med Decis Making. 2010. PMID: 20551473
-
Medicare's national coverage determinations in diagnostic radiology: examining evidence and setting limits.Acad Radiol. 2012 Sep;19(9):1060-5. doi: 10.1016/j.acra.2012.05.005. Epub 2012 Jun 29. Acad Radiol. 2012. PMID: 22748382
-
Medicare's national coverage decisions for technologies, 1999-2007.Health Aff (Millwood). 2008 Nov-Dec;27(6):1620-31. doi: 10.1377/hlthaff.27.6.1620. Health Aff (Millwood). 2008. PMID: 18997221
-
Medicare's national coverage decisions, 1999-2003: quality of evidence and review times.Health Aff (Millwood). 2005 Jan-Feb;24(1):243-54. doi: 10.1377/hlthaff.24.1.243. Health Aff (Millwood). 2005. PMID: 15647237
-
Inadequate prescription-drug coverage for Medicare enrollees--a call to action.N Engl J Med. 1999 Mar 4;340(9):722-8. doi: 10.1056/NEJM199903043400909. N Engl J Med. 1999. PMID: 10053183
Cited by
-
Teamwork in hip preservation: the ISHA 2019 Annual Scientific Meeting.J Hip Preserv Surg. 2020 Oct 9;7(Suppl 1):2-21. doi: 10.1093/jhps/hnaa037. eCollection 2020 Oct. J Hip Preserv Surg. 2020. PMID: 33072394 Free PMC article.
-
Utilization of Advanced Cardiovascular Therapies in the United States and Canada: An Observational Study of New York and Ontario Administrative Data.Circ Cardiovasc Qual Outcomes. 2020 Jan;13(1):e006037. doi: 10.1161/CIRCOUTCOMES.119.006037. Epub 2020 Jan 20. Circ Cardiovasc Qual Outcomes. 2020. PMID: 31957474 Free PMC article.
-
Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016: A cross-sectional study.Medicine (Baltimore). 2018 Oct;97(40):e12715. doi: 10.1097/MD.0000000000012715. Medicine (Baltimore). 2018. PMID: 30290675 Free PMC article.
-
Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review.Pharmacoeconomics. 2018 Mar;36(3):323-340. doi: 10.1007/s40273-017-0586-1. Pharmacoeconomics. 2018. PMID: 29124632
-
Variation in Private Payer Coverage of Rheumatoid Arthritis Drugs.J Manag Care Spec Pharm. 2016 Oct;22(10):1176-81. doi: 10.18553/jmcp.2016.22.10.1176. J Manag Care Spec Pharm. 2016. PMID: 27668566 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
